OKYO Pharma Stock (NASDAQ:OKYO)
Previous Close
$1.53
52W Range
$1.34 - $3.20
50D Avg
$1.55
200D Avg
$1.74
Market Cap
$55.63M
Avg Vol (3M)
$105.64K
Beta
0.04
Div Yield
-
OKYO Company Profile
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.